INS and type 2 diabetes mellitus: Since it has been well recognized that type 2 diabetes in east Asians is primarily characterized by impaired insulin secretion (3), phase 3 clinical trials, the Trials of Imeglimin for Efficacy and Safety (TIMES 1–3), demonstrated both efficacy and safety of imeglimin in Japanese individuals with type 2 diabetes (4–6).